title: Eplerenone after myocardial infarction?
abstract: Each year in the UK, an estimated 50,000 patients develop major left ventricular systolic dysfunction (LVSD) and heart failure following a myocardial infarct.1 Such patients have a particularly poor prognosis. Eplerenone (Inspra - Pfizer) is an aldosterone-receptor antagonist for patients who have LVSD and heart failure following a recent myocardial infarct. Here, we discuss whether such patients should receive this drug.
mesh_terms: D000075202:Contraindications; D016527:Drug Costs; D000077545:Eplerenone; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000191:economics / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000191:economics; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000077545:Eplerenone